Metabolic Insights: the Impact of F-18 FDG PET/CT in Adult Lymphoma
1 other identifier
observational
62
1 country
1
Brief Summary
- 1.To assess staging accuracy of F-18 FDG PET/CT in lymphoma
- 2.Determine the role of F-18 FDG PET/CT in monitoring treatment response and detecting relapse or residual disease in lymphoma
- 3.To evaluate FDG uptake correlation with histopathological subtypes and immunophenotypes as a prognostic factor.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Jan 2025
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 1, 2024
CompletedFirst Posted
Study publicly available on registry
December 17, 2024
CompletedStudy Start
First participant enrolled
January 1, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
June 1, 2027
December 17, 2024
December 1, 2024
2 years
December 1, 2024
December 12, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
primary
Treatment Response Using Deauville Score for FDG Uptake Evaluation: Evaluate FDG uptake using the 5-point scale: 1. No uptake above background 2. Uptake ≤ mediastinum 3. Uptake \> mediastinum but ≤ liver 4. Moderately increased compared to liver 5. Markedly increased compared to liver X: New uptake, unlikely related to lymphoma
3 years
Secondary Outcomes (1)
secondary
3 years
Interventions
18 flurodeoxy glucose PET/CT
Eligibility Criteria
This is a prospective study data collected from a single-center Clinical Oncology and Nuclear Medicine Department - Assuit University Hospital, which included 62 lymphoma cases who underwent F-18 FDG PET/CT for disease staging, treatment response assessment, or post-treatment monitoring.
You may qualify if:
- Age: Patient must be older than 18 years.
- Confirmed Diagnosis of Lymphoma: Patient must have a confirmed diagnosis of lymphoma based on histopathology and immunophenotyping.
You may not qualify if:
- Patients with Known concomitant malignancy.
- Pregnancy: Pregnant women due to the potential risks associated with radiation exposure from the PET/CT scan.
- Severe Renal or Hepatic Impairment: Patients with significant renal or hepatic dysfunction that could affect FDG metabolism or excretion.
- Uncontrolled Diabetes: Patients with uncontrolled diabetes (blood glucose \>200 mg/dL), as it can affect FDG uptake and PET/CT results.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Nuclear medicine- Assiut University Hospital
Asyut, Egypt
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Esraa R Hassan, MD
South Egypt Cancer Institute
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 6 Months
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Assisstant lecturer
Study Record Dates
First Submitted
December 1, 2024
First Posted
December 17, 2024
Study Start
January 1, 2025
Primary Completion (Estimated)
December 31, 2026
Study Completion (Estimated)
June 1, 2027
Last Updated
December 17, 2024
Record last verified: 2024-12